Lubiprostone ( DrugBank: Lubiprostone )

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	4
13	Multiple sclerosis/Neuromyelitis optica	1
290	Chronic nonspecific multiple ulcers of the small intestine	1
299	Cystic fibrosis	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000022022	2016/05/10	10/05/2016	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease	Parkinson diseaseChronic constipation	Study drug group: A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment	Dokkyo Medical University	NULL	Complete: follow-up complete	20years-old	90years-old	Male and Female	64	Not selected	Japan
2	JPRN-UMIN000022023	2016/05/10	10/05/2016	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-	A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora-	Parkinson diseaseChronic constipation	Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen	Dokkyo Medical University	NULL	Complete: follow-up complete	20years-old	90years-old	Male and Female	64	Not selected	Japan
3	NCT00669461 (ClinicalTrials.gov)	June 2009	28/4/2008	Lubiprostone as a Treatment for Constipation in Parkinson's Disease	Lubiprostone as a Treatment for Constipation in Parkinson's Disease	Constipation;Parkinson's Disease	Drug: Lubiprostone	University of Arkansas	Takeda	Terminated	50 Years	85 Years	All	1	N/A	United States
4	NCT00908076 (ClinicalTrials.gov)	February 2009	21/5/2009	Amitiza in Constipation Associated With PD (Parkinson's Disease)	Randomized Double-Blind Placebo-Controlled Trial of Lubiprostone in the Treatment of Constipation Associated With Parkinson's Disease	Parkinson's Disease	Drug: LUBIPROSTONE	Baylor College of Medicine	University of South Florida	Completed	18 Years	85 Years	All	78	Phase 4	United States

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01236534 (ClinicalTrials.gov)	November 2010	4/11/2010	Lubiprostone in Patients With Multiple Sclerosis Associated Constipation	Single-center, Randomized, Double-blind, Placebo-controlled, Parallel-groups Study of Lubiprostone in Patients With Multiple Sclerosis-Associated Constipation	Multiple Sclerosis;Constipation	Drug: Lubiprostone;Drug: Placebo	University of Rochester	Takeda	Completed	18 Years	N/A	All	21	Phase 4	United States

290. Chronic nonspecific multiple ulcers of the small intestine

Clinical trial : 1 / Drug : 1 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathway : 1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000030327	2017/12/25	22/12/2017	Proof-of-concept clinical trial of lubiprostone's effect on chronic enteropathy associated with SLCO2A1	Proof-of-concept clinical trial of lubiprostone's effect on chronic enteropathy associated with SLCO2A1 - LEAC study	Nonspecific multiple ulcers in the small intestine unrelated to NSAID (Chronic enteropathy associated with SLCO2A1: CEAS)	lubiprostone(12 micrograms) for 8 weeks	Fujita Health University, Department of Gastroenterology	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	8	Phase 1,2	Japan

299. Cystic fibrosis

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00706004 (ClinicalTrials.gov)	July 2008	25/6/2008	Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis	Short Term Safety and Efficacy of Lubiprostone in Adults With Cystic Fibrosis	Constipation;Cystic Fibrosis	Drug: lubiprostone	University of Arkansas	Takeda Pharmaceuticals North America, Inc.	Completed	18 Years	N/A	All	9	N/A	United States